Meningococcal glycoconjugate vaccines

Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults

(2010) R. Gasparini et al.   Clinical and Vaccine Immunology

Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines

(2010) Gregory A. Poland   CLINICAL INFECTIOUS DISEASES

Advances in the Development of Vaccines againstNeisseria meningitidis

(2010) Lionel K.K. Tan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines

(2010) A. Arguedas et al.   VACCINE

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents

(2009) Lisa A. Jackson et al.   CLINICAL INFECTIOUS DISEASES

Conjugate Meningococcal Vaccines: Lifesaving or Inefficient Use or Both—No Easy Answer

(2009) Stephen I. Pelton   CLINICAL INFECTIOUS DISEASES

Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

(2009) Amanda C. Cohn et al.   CLINICAL INFECTIOUS DISEASES

Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine

(2009) Ener Cagri Dinleyici et al.   Expert Review of Vaccines

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

(2009) Caroline L Trotter et al.   Expert Review of Vaccines

10-valent pneumococcal nontypeableHaemophilus influenzaePD conjugate vaccine: Synflorix™

(2009) Roman Prymula et al.   Expert Review of Vaccines

Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from Africa

(2009) P. T. Beernink et al.   JOURNAL OF INFECTIOUS DISEASES

Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development

(2009) Helena Lo et al.   LANCET INFECTIOUS DISEASES

Emergence of Ciprofloxacin-ResistantNeisseria meningitidisin North America

(2009) Henry M. Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of Routinely Used Childhood Vaccines When Coadministered With the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)

(2009) Markus Knuf et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: The Italian epidemiological scenario

(2009) R. Gasparini et al.   VACCINE

Meningococcal carriage and disease—Population biology and evolution

(2009) Dominique A. Caugant et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age

(2009) S. Black et al.   VACCINE

Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants

(2008) Matthew D. Snape et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE